

# Fernando J Martinez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3550550/fernando-j-martinez-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287  
papers

35,222  
citations

68  
h-index

186  
g-index

327  
ext. papers

44,863  
ext. citations

10.4  
avg, IF

7.02  
L-index

#	Paper	IF	Citations
287	Screening for Chronic Obstructive Pulmonary Disease: Unmet Needs and Future Considerations.. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 126-128	27.4	
286	Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.. <i>Respiratory Research</i> , <b>2022</b> , 23, 85	7.3	2
285	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR.. <i>Science of the Total Environment</i> , <b>2022</b> , 829, 154694	10.2	1
284	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.. <i>Respiratory Research</i> , <b>2022</b> , 23, 97	7.3	0
283	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2022</b> , 205, e18-e47	10.2	38
282	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. <i>Respiratory Medicine</i> , <b>2022</b> , 197, 106857	4.6	0
281	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	5
280	Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. <i>Journal of Global Health</i> , <b>2021</b> , 11, 15003	4.3	3
279	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	7
278	The influence of social support on COPD outcomes mediated by depression. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245478	5.7	3
277	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. <i>Scientific Reports</i> , <b>2021</b> , 11, 4916	4.9	2
276	InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. <i>Respiratory Research</i> , <b>2021</b> , 22, 130	7.3	2
275	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. <i>Respiratory Research</i> , <b>2021</b> , 22, 126	7.3	3
274	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. <i>Genome Medicine</i> , <b>2021</b> , 13, 66	14.4	6
273	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>International Journal of COPD</i> , <b>2021</b> , 16, 1477-1496	3	1
272	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1241-1254	35.1	20
271	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2

270	Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. <i>Pulmonary Therapy</i> , <b>2021</b> , 7, 471-486	3.6	2
269	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 494-503	5.8	5
268	Future concepts in bronchodilation for COPD: dual- monotherapy. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	1
267	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. <i>Annals of the American Thoracic Society</i> , <b>2021</b> ,	4.7	2
266	Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	10
265	Reversal of emphysema by restoration of pulmonary endothelial cells. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	8
264	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 24-36	10.2	127
263	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 211-220	10.2	20
262	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. <i>Chest</i> , <b>2021</b> , 159, 985-995	5.3	2
261	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 987-997	10.2	10
260	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 689-698	10.2	10
259	Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 458-470	10.2	6
258	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 957-968	10.2	13
257	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 553-564	10.2	38
256	Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial. <i>Chest</i> , <b>2021</b> , 159, 1812-1820	5.3	7
255	Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. <i>Respiratory Medicine</i> , <b>2021</b> , 176, 106278	4.6	1
254	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	3
253	Natural history and mechanisms of COPD. <i>Respirology</i> , <b>2021</b> , 26, 298-321	3.6	12

252	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2021</b> , 8, 326-335	2.7	
251	Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. <i>International Journal of COPD</i> , <b>2021</b> , 16, 179-189	3	7
250	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. <i>Npj Biofilms and Microbiomes</i> , <b>2021</b> , 7, 14	8.2	9
249	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 197-208	10.2	7
248	Ratio of FEV/Slow Vital Capacity of Chest, <b>2021</b> , 160, 94-103	5.3	0
247	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, e3-e23	10.2	1
246	Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19. <i>Scientific Reports</i> , <b>2021</b> , 11, 15872	4.9	8
245	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. <i>Respiratory Medicine</i> , <b>2021</b> , 185, 106509	4.6	5
244	Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States. <i>Respiratory Research</i> , <b>2021</b> , 22, 225	7.3	1
243	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2301-2322	3	2
242	Association of circulating cell-free double-stranded DNA and metabolic derangements in idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2021</b> ,	7.3	2
241	Letter to Editor Regarding the OCEAN Study [Letter]. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2501-2503		
240	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 536-545	10.2	4
239	Perplexing mortality data from triple therapy trials in COPD - Author's reply. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, e96	35.1	0
238	Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1087-1089	35.1	
237	Does Evaluation and Management of COPD Follow Therapeutic Strategy Recommendations?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2021</b> , 8, 230-242	2.7	3
236	Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2021</b> , 8,	2.7	6
235	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	1

234	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2021</b> , 15, 17534666211034329	4.9	3
233	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease.. <i>Respiratory Research</i> , <b>2021</b> , 22, 316	7.3	1
232	Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort. <i>International Journal of COPD</i> , <b>2020</b> , 15, 2467-2476	3	3
231	Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis. <i>Chest</i> , <b>2020</b> , 158, 1420-1430	5.3	7
230	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
229	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. <i>Chest</i> , <b>2020</b> , 157, 1391-1392	5.3	0
228	Update in Interstitial Lung Disease 2019. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 500-507	10.2	3
227	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. <i>Respiratory Research</i> , <b>2020</b> , 21, 128	7.3	2
226	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1135-1142	3	11
225	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2268-2280	27.4	34
224	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 35-48	59.2	121
223	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 660-671	10.2	33
222	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 1508-1516	10.2	63
221	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. <i>Respiratory Research</i> , <b>2020</b> , 21, 68	7.3	15
220	Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. <i>Thorax</i> , <b>2020</b> , 75, 735-743	7.3	10
219	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 1237-1243	10.2	14
218	A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. <i>Respiratory Research</i> , <b>2020</b> , 21, 47	7.3	17
217	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. <i>Chest</i> , <b>2020</b> , 157, 1506-1512	5.3	18

216	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. <i>International Journal of COPD</i> , <b>2020</b> , 15, 99-106	3	3
215	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial. <i>Chest</i> , <b>2020</b> , 158, 529-538	5.3	1
214	Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. <i>BMJ Open Respiratory Research</i> , <b>2020</b> , 7,	5.6	25
213	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	19
212	The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 540-554	10.2	17
211	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 106-115	11.5	24
210	Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, 329-337	5.3	0
209	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , <b>2020</b> , 21, 177	7.3	8
208	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. <i>Scientific Reports</i> , <b>2020</b> , 10, 10562	4.9	10
207	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. <i>Scientific Reports</i> , <b>2020</b> , 10, 20133	4.9	0
206	Obesity and COVID-19 in New York City: A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 855-858	8	47
205	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 925-934	35.1	77
204	Identification of a unique temporal signature in blood and BAL associated with IPF progression. <i>Scientific Reports</i> , <b>2020</b> , 10, 12049	4.9	4
203	Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1887-1898	3	1
202	Risk factors for disease progression in idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2020</b> , 75, 78-80	7.3	10
201	Clinical Characteristics of Covid-19 in New York City. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2372-2374	33.4	1311
200	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, e56-e69	10.2	104
199	The natural history of progressive fibrosing interstitial lung diseases. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	67

198	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 780-790	35.1	61
197	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 µg and 160/18/9.6 µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , <b>2019</b> , 158, 59-66	4.6	16
196	Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV <sub>1</sub> /FVC. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 58-68	4.6	20
195	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. <i>BMJ Open Respiratory Research</i> , <b>2019</b> , 6, e000431	5.6	18
194	Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD. <i>Cellular and Molecular Bioengineering</i> , <b>2019</b> , 12, 165-177	3.9	2
193	Effect of daily azithromycin therapy and adherence on readmission risk in COPD. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	4
192	Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 355-367	1.7	9
191	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	722
190	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 721-731	10.2	22
189	Regional differences in rate of FEV <sub>1</sub> decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	1
188	Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 497-508	35.1	72
187	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 487-496	35.1	61
186	The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	24
185	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 575-581	10.2	62
184	Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. <i>Chest</i> , <b>2019</b> , 155, 908-917	5.3	9
183	Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. <i>Academic Radiology</i> , <b>2019</b> , 26, 306-312	4.3	8
182	Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. <i>Academic Radiology</i> , <b>2019</b> , 26, 217-223	4.3	29
181	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , <b>2019</b> , 155, 168-177	5.3	26

180	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. <i>Scientific Reports</i> , <b>2019</b> , 9, 11367	4.9	10
179	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1505-1512	10.2	30
178	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). <i>Respiratory Research</i> , <b>2019</b> , 20, 153	7.3	12
177	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 745-756	35.1	85
176	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1146-1153	10.2	33
175	Metoprolol for the Prevention of Acute Exacerbations of COPD. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2304-2314	59.2	51
174	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , <b>2019</b> , 9, 14802	4.9	10
173	Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2019</b> , 6, 64-73	2.7	22
172	COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2019</b> , 6, 384-399	2.7	61
171	Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1127-1138	10.2	103
170	It's difficult, it's life changing what happens to you: patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study. <i>BMJ Open Respiratory Research</i> , <b>2019</b> , 6, e000522	5.6	6
169	Relationship between diffusion capacity and small airway abnormality in COPDGene. <i>Respiratory Research</i> , <b>2019</b> , 20, 269	7.3	13
168	Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. <i>International Journal of COPD</i> , <b>2019</b> , 14, 2927-2938	3	3
167	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 200-208	4.7	19
166	Why Does an Aging Smoker's Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 279-285	10.2	17
165	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 336-347	10.2	41
164	Effects of baseline symptom burden on treatment response in COPD. <i>International Journal of COPD</i> , <b>2019</b> , 14, 181-194	3	7
163	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report From the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 29-39	4.7	8



162	Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1061-1065	10.2	6
161	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 439-446	4.7	8
160	Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. <i>Chest</i> , <b>2019</b> , 155, 699-711	5.3	87
159	Pulmonary hypertension in chronic lung disease and hypoxia. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	231
158	An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 169-181	15.9	50
157	EBlocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 608-614	4.7	14
156	Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 730-738	10.2	15
155	Update in Chronic Obstructive Pulmonary Disease 2017. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1534-1539	10.2	3
154	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1671-1680	59.2	511
153	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 51-57	10.2	97
152	Human airway branch variation and chronic obstructive pulmonary disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E974-E981	11.5	53
151	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1540-1551	10.2	94
150	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	17
149	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	32
148	Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. <i>Respiratory Research</i> , <b>2018</b> , 19, 30	7.3	20
147	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 808-816	4.7	16
146	Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 429-432	11.5	5
145	Genome-wide association study of lung function and clinical implication in heavy smokers. <i>BMC Medical Genetics</i> , <b>2018</b> , 19, 134	2.1	19

144	Precision medicine in COPD: where are we and where do we need to go?. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	33
143	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. <i>Chest</i> , <b>2018</b> , 154, 266-273	5.3	15
142	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1126-1137	15.1	31
141	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 3128-3134	9.5	17
140	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. <i>International Journal of COPD</i> , <b>2018</b> , 13, 1901-1912	3	7
139	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 707-714	35.1	74
138	Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 797-798	59.2	66
137	Chronic obstructive pulmonary disease subpopulations and phenotyping. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 1961-1971	11.5	29
136	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. <i>Respiratory Medicine</i> , <b>2018</b> , 140, 87-93	4.6	9
135	Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	19
134	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1036-1044 <sup>10.2</sup>	10.2	109
133	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , <b>2018</b> , 153, 94-104	5.3	47
132	Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort. <i>Respiratory Research</i> , <b>2018</b> , 19, 257	7.3	10
131	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. <i>Respiratory Research</i> , <b>2018</b> , 19, 223	7.3	11
130	Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes. <i>Chest</i> , <b>2018</b> , 154, 984-985	5.3	3
129	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Respiratory Research</i> , <b>2018</b> , 19, 178	7.3	12
128	Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment. <i>Chest</i> , <b>2018</b> , 154, 978-979	5.3	8
127	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 747-758	35.1	157

126	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, e44-e68	10.2	1426
125	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1268-1278	10.2	43
124	Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	32
123	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2017</b> , 18, 8	7.3	20
122	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , <b>2017</b> , 22, 575-601	3.6	228
121	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	398
120	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 557-582	10.2	1682
119	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 208-219	10.2	89
118	GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease. <i>Respiratory Research</i> , <b>2017</b> , 18, 42	7.3	15
117	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , <b>2017</b> , 103, 1536-1542	5.1	34
116	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1249-1254	10.2	105
115	Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment. <i>Chest</i> , <b>2017</b> , 151, 1173-1174	5.3	9
114	Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 1164-1167.e6	11.5	22
113	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , <b>2017</b> , 14, 636-642	4.7	21
112	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. <i>Scientific Reports</i> , <b>2017</b> , 7, 46560	4.9	28
111	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. <i>Chest</i> , <b>2017</b> , 151, 340-357	5.3	82
110	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	247
109	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 61-71	35.1	52

108	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. <i>Lancet Respiratory Medicine,the</i> , <b>2017</b> , 5, 22-32	35.1	142
107	Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 690-699	10.2	119
106	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. <i>BMJ Open Respiratory Research</i> , <b>2017</b> , 4, e000186	5.6	15
105	Idiopathic pulmonary fibrosis. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17074	51.1	395
104	Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	57
103	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	50
102	Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. <i>Respiratory Medicine</i> , <b>2017</b> , 131, 229-235	4.6	19
101	Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. <i>Chest</i> , <b>2017</b> , 152, 1169-1178	5.3	25
100	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , <b>2017</b> , 131, 27-34	4.6	21
99	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. <i>BMJ Open Respiratory Research</i> , <b>2017</b> , 4, e000252	5.6	20
98	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine,the</i> , <b>2017</b> , 5, 956-967	35.1	140
97	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. <i>Annals of the American Thoracic Society</i> , <b>2017</b> , 14, 1646-1654	4.7	54
96	Effect of roflumilast in patients with severe COPD and a history of hospitalisation. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	24
95	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine,the</i> , <b>2017</b> , 5, 619-626	35.1	148
94	Azithromycin and risk of COPD exacerbations in patients with and without <i>Helicobacter pylori</i> . <i>Respiratory Research</i> , <b>2017</b> , 18, 109	7.3	3
93	Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). <i>Respiratory Research</i> , <b>2017</b> , 18, 124	7.3	22
92	The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1372-1379	10.2	65
91	Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 921-929	10.2	68

90	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 881-888	10.2	38
89	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 748-756	10.2	62
88	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 473-481	10.2	73
87	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 17-22	10.2	27
86	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S10-S13	4.6	11
85	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184606	3.7	11
84	Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS. <i>Tomography</i> , <b>2017</b> , 3, 138-145	3.1	3
83	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 541-9	10.2	47
82	Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD). <i>Health and Quality of Life Outcomes</i> , <b>2016</b> , 14, 104	3	7
81	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 473-526	35.1	57
80	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 265-75	10.2	653
79	Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. <i>Chest</i> , <b>2016</b> , 149, 491-498	5.3	52
78	Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 178-84	10.2	194
77	The Microbiome and the Respiratory Tract. <i>Annual Review of Physiology</i> , <b>2016</b> , 78, 481-504	23.1	426
76	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006011	6	64
75	Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159878	3.7	31
74	The Human Microbiome in the Lung: Are Infections Contributing to Lung Health and Disease?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2016</b> , 3, 466-472	2.7	3
73	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2016</b> , 4, 7-20	2.7	6

72	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension□ Delivery Technology Versus Foradil□ Aerolizer□ in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2016</b> , 4, 21-33	2.7	5
71	Insight into Best Variables for COPD Case Identification: A Random Forests Analysis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2016</b> , 3, 406-418	2.7	9
70	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. <i>Thorax</i> , <b>2016</b> , 71, 411-420	7.3	10
69	Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. <i>Chest</i> , <b>2016</b> , 149, 927-35	5.3	25
68	Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 948-960	10.2	73
67	Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1242-1251	10.2	97
66	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1817-26	4.0	263
65	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1811-21	59.2	355
64	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. <i>Respiratory Medicine</i> , <b>2016</b> , 120, 16-24	4.6	18
63	Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling. <i>Respiratory Medicine</i> , <b>2016</b> , 118, 88-95	4.6	38
62	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 794-806	10.2	132
61	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine, the</i> , <b>2016</b> , 4, 708-719	35.1	487
60	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 27-34	4.7	98
59	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, e3-19	10.2	1122
58	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine, the</i> , <b>2015</b> , 3, 388-96	35.1	57
57	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. <i>Lancet, The</i> , <b>2015</b> , 385, 1789-1798	4.0	168
56	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 243-9	13.6	35
55	Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 240-9	3.3	37

54	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1740-50	13.6	64
53	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1475-82	10.2	187
52	Older adults with chronic lung disease report less limitation compared with younger adults with similar lung function impairment. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 21-6	4.7	10
51	Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes. <i>BMC Genomics</i> , <b>2015</b> , 16, 924	4.5	50
50	Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population. <i>Npj Primary Care Respiratory Medicine</i> , <b>2015</b> , 25, 15024	3.2	14
49	Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. <i>Respiratory Research</i> , <b>2015</b> , 16, 94	7.3	37
48	The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans. <i>Tomography</i> , <b>2015</b> , 1, 69-77	3.1	15
47	Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS). <i>Academic Radiology</i> , <b>2015</b> , 22, 186-94	4.3	67
46	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 385, 857-66	4.0	248
45	Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2015</b> , 2, 103-121	2.7	27
44	Smoking-related idiopathic interstitial pneumonia. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 594-602	13.6	27
43	Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3605-13	9.7	94
42	The role of the microbiome in exacerbations of chronic lung diseases. <i>Lancet, The</i> , <b>2014</b> , 384, 691-702	4.0	275
41	Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2014</b> , 146, 1256-1262	5.3	24
40	Basal gene expression by lung CD4+ T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. <i>PLoS ONE</i> , <b>2014</b> , 9, e96421	3.7	17
39	Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e103840	3.7	36
38	Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. <i>Frontiers in Medicine</i> , <b>2014</b> , 1,	4.9	34
37	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). <i>Thorax</i> , <b>2014</b> , 69, 491-4	7.3	212

36	Cell-associated bacteria in the human lung microbiome. <i>Microbiome</i> , <b>2014</b> , 2, 28	16.6	61
35	Changes in the lung microbiome following lung transplantation include the emergence of two distinct <i>Pseudomonas</i> species with distinct clinical associations. <i>PLoS ONE</i> , <b>2014</b> , 9, e97214	3.7	123
34	Long-acting bronchodilators in COPD: an evolving story. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 499-503	5.1	0
33	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 1017-22	13.6	65
32	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 733-48	10.2	2176
31	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 347-65	10.2	3654
30	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 369-76	35.1	276
29	Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 641-9	8	327
28	MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis--validation of two novel biomarker assays. <i>PLoS ONE</i> , <b>2013</b> , 8, e84934	3.7	110
27	Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis. <i>Fibrogenesis and Tissue Repair</i> , <b>2012</b> , 5, S3		17
26	Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. <i>Nature Medicine</i> , <b>2012</b> , 18, 1711-5	50.5	463
25	Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1968-77	59.2	992
24	An Assessment of Epithelial and Mesenchymal Phenotypes in Experimental and Clinical Pulmonary Fibrosis. <i>ISRN Pulmonology</i> , <b>2012</b> , 2012, 1-11		
23	Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. <i>Chest</i> , <b>2012</b> , 142, 704-711	5.3	22
22	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 788-824	10.2	4665
21	The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development. <i>Lancet, The</i> , <b>2011</b> , 378, 1027-37	4.0	78
20	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 92-9	10.2	333
19	Chronic obstructive pulmonary disease phenotypes: the future of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 598-604	10.2	678



18	Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. <i>International Journal of COPD</i> , <b>2010</b> , 5, 1-10	3	43
17	Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S85-S96	15.1	284
16	Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2008</b> , 5, 85-95	2	157
15	Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings. <i>American Journal of Roentgenology</i> , <b>2008</b> , 191, 1032-9	5.4	46
14	Sex differences in severe pulmonary emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 243-52	10.2	249
13	Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , <b>2007</b> , 4, 647-58		12
12	Acute exacerbations of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 636-43	10.2	823
11	Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 81-95		38
10	Update in diffuse parenchymal lung diseases 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1066-71	10.2	13
9	Predictors of mortality in patients with emphysema and severe airflow obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1326-34	10.2	310
8	Acute exacerbation of chronic bronchitis: expanding short-course therapy. <i>International Journal of Antimicrobial Agents</i> , <b>2005</b> , 26 Suppl 3, S156-63	14.3	6
7	Is it asthma or COPD? The answer determines proper therapy for chronic airflow obstruction. <i>Postgraduate Medicine</i> , <b>2005</b> , 117, 19-26	3.7	26
6	Surgical therapy for chronic obstructive pulmonary disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2005</b> , 26, 167-91	3.9	39
5	Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 904-10	10.2	450
4	Acute bronchitis: state of the art diagnosis and therapy. <i>Comprehensive Therapy</i> , <b>2004</b> , 30, 55-69		12
3	Patient selection for lung volume reduction surgery. <i>Chest Surgery Clinics of North America</i> , <b>2003</b> , 13, 669-85		5
2	Detecting osteoporosis. Beyond the history and physical examination. <i>Postgraduate Medicine</i> , <b>1998</b> , 103, 45-7, 51-2, 62-3 passim	3.7	13
1	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. <i>Patient Related Outcome Measures</i> , Volume 13, 53-68	2.9	0

